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Abstract 
Background: Systemic lupus erythematosus (SLE) is a chronic, autoimmune and multisystemic disease. Recent 
studies with functional and structural magnetic resonance imaging and cognitive tests report an unexpectedly high 
frequency of central nervous system involvement, even in patients with asymptomatic SLE. The purpose of this study 
was to identify early signs of retinal neurodegeneration by comparing the thickness of the peripapillary retinal nerve 
fiber layer (pRNFL) and all macular layers between patients with SLE without ophthalmologic manifestations and 
healthy controls. The effect of disease duration and systemic comorbidities was also studied.
Methods: Cross‑sectional study, in which all participants underwent a complete ophthalmologic evaluation includ‑
ing retinal segmentation analysis with spectral domain‑optical coherence tomography. Patients with SLE also received 
a detailed autoimmune disease specialist evaluation to assess the disease activity state and systemic involvement. For 
pRNFL thickness, the global and six peripapillary sectors were determined. Each macular layer thickness was deter‑
mined in the nine Early Treatment Diabetic Retinopathy Study (ETDRS) subfields. A multiple linear regression analysis 
was performed to control for the effect of potential demographic, ophthalmic and systemic confounders. A second 
multivariable analysis, including patients with SLE only, was performed to assess the effect of disease‑specific vari‑
ables on the outcome measures.
Results: Sixty‑eight eyes of 68 patients with SLE and 50 eyes of 50 healthy controls were considered. The pRNFL 
was significantly thinner in the SLE group globally (p = 0.026) and in the temporal superior (p = 0.007) and temporal 
(p = 0.037) sectors. In patients with SLE, chronic medication for hypercholesterolemia, hypertension and anticoagu‑
lants were associated with a significant thinning of the pRNFL. Patients with SLE presented significant thinning in the 
photoreceptor layer in five ETDRS areas (p < 0.05). Shorter disease duration was associated with greater photoreceptor 
thinning in all ETDRS subfields. Neuropsychiatric SLE, higher disease activity and cardiovascular risk factors were asso‑
ciated with a thinner photoreceptor layer. No differences were observed in overall retinal thickness or the remaining 
macular layers.
Conclusion: Patients with SLE present early signs of retinal neurodegeneration, as evidenced by a reduction in the 
photoreceptor layer and pRNFL. These signs are more pronounced in patients with higher cardiovascular risk burden 
or neuropsychiatric involvement.
© The Author(s) 2020. This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, 
adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and 
the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material 
in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material 
is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the 
permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creat iveco 
mmons .org/licen ses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creat iveco mmons .org/publi cdoma in/
zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
Open Access
International Journal
of Retina and Vitreous
*Correspondence:  arnaldomiguelsantos@gmail.com
11 Serviço de Oftalmologia, Hospital de Santo António dos Capuchos, 
Alameda de Santo António dos Capuchos, 1169‑050 Lisbon, Portugal
Full list of author information is available at the end of the article
Page 2 of 11Dias‑Santos et al. Int J Retin Vitr            (2020) 6:15 
Background
Systemic lupus erythematosus (SLE) is a chronic auto-
immune disease that can affect multiple organ systems. 
Involvement of the central nervous system (CNS) occurs 
in 12% to 95% of patients with SLE [1]. A large number 
of manifestations ranging from distinct neurologic disor-
ders such as stroke, aseptic meningitis and Guillain-Barré 
syndrome to more subtle dysfunctions such as head-
ache, mood disorders and cognitive dysfunction have 
been included by the American College of Rheumatol-
ogy under the designation of neuropsychiatric systemic 
lupus erythematosus (NP-SLE) [2]. Overall, it is associ-
ated with a significant increase in morbidity and mortal-
ity [3]. However, the absence of NP-SLE biomarkers and 
a lack of specificity for neuropsychiatric events that are 
common in the general population render the diagnosis a 
challenge. Moreover, the frequency of some sort of neu-
rologic impairment in SLE is unexpectedly high, even in 
asymptomatic patients without NP-SLE criteria [4]. Of 
note, patients with non-NP-SLE perform worse in cogni-
tive tests and present a significantly higher rate of struc-
tural and functional abnormalities in magnetic resonance 
imaging when compared to healthy controls [5]. Addi-
tionally, the brains of recently diagnosed patients with 
SLE, without neurologic symptoms, present abnormally 
high blood flow and glucose consumption (hypermetab-
olism) in the white matter. This phenomenon was more 
prominent in patients with poor systemic disease control 
[6]. This finding suggests that neurologic involvement 
with CNS inflammation and subsequent neurodegen-
eration may be present early in the course of the disease 
before the development of NP-SLE.
Spectral domain optical coherence tomography (SD-
OCT) is a safe and objective method that permits high-
resolution cross-sectional images of the retina. In the last 
few years, this technique has evolved, allowing precise 
qualitative and quantitative evaluation of all retinal layers 
with high repeatability and reproducibility [7]. This evo-
lution expanded its applications beyond ophthalmic dis-
eases, and SD-OCT is now a well-established biomarker 
of neurodegenerative disorders such as multiple sclerosis 
[8], Alzheimer’s disease [9] and Parkinson’s disease [10]. 
The role of OCT as a biomarker of SLE-associated neu-
rodegeneration has been addressed only in a few studies, 
which have yielded inconsistent results. However, these 
were pilot studies with small sample sizes, which only 
evaluated total retinal thickness or focused on some reti-
nal layers [11–13].
This study aimed to compare the thickness of all macu-
lar layers as well as the peripapillary retinal nerve fiber 
layer (pRNFL) thickness between patients with SLE with-
out ophthalmologic manifestations and a healthy control 
group. The relationship between retinal thickness and 
demographic characteristics, as well as disease duration, 
hydroxychloroquine intake and cumulative dosage and 
systemic comorbidities such as neuropsychiatric SLE, 




This was a cross-sectional study performed at the Oph-
thalmology Department and at the Autoimmune Disease 
Units of the Central Lisbon Hospital University Center 
between August 2017 and August 2018. Consecutive 
patients with SLE were screened for inclusion/exclusion 
criteria. All patients fulfilled the 1997 revised American 
College of Rheumatology criteria for the diagnosis of SLE 
[14] and were aged between 18 and 80 years old.
A sex-matched control group with an age range 
between 18 and 80  years old was randomly recruited 
from the General Ophthalmology Department. Auto-
immune diseases were ruled out in this group based on 
patient-reported past medical history and on general 
practitioner medical records.
The exclusion criteria for both study groups were a 
spherical equivalent > 5 diopters, axial length > 25  mm 
or keratic astigmatism > 3 diopters, diabetes mellitus, 
pregnancy, signs or previous history of optic neuropa-
thy, retinopathy or choroidopathy (namely, lupus-related, 
age-related macular degeneration, vascular occlusion, 
macular dystrophy, hydroxychloroquine retinopathy, 
glaucoma, ocular hypertension or neurodegenerative dis-
eases such as Alzheimer’s or Parkinson’s disease), ocular 
tumor, previous episodes of intraocular inflammation, 
history of intraocular or refractive surgery and substan-
tial media opacities that compromised fundus imaging.
This study was approved by the Institutional Ethics 
Committee. All participants gave their written informed 
consent, and the principles of the Declaration of Helsinki 
were followed.
Study procedures
A complete ophthalmologic evaluation was performed 
on all patients, where demographic, background medi-
cal history, full ophthalmological examination with best 
Keywords: Neurodegeneration, Peripapillary retinal nerve fiber layer, Photoreceptors, Spectral domain optical 
coherence tomography, Systemic lupus erythematosus
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corrected visual acuity (BCVA) testing, slit-lamp biomi-
croscopy, dilated fundus examination, Goldmann appla-
nation tonometry, optic biometry (using Lenstar LS  900®, 
Haag Streit AG, Koeniz, Switzerland) and SD-OCT were 
performed. Blood pressure was measured before SD-
OCT. Patients with SLE currently or previously treated 
with hydroxychloroquine also underwent fundus autoflu-
orescence imaging and 10-2 macular automated thresh-
old visual field testing (using Octopus  900®, Haag Streit 
AG, Koeniz, Switzerland) to exclude retinal toxicity, in 
accordance with the American Academy of Ophthalmol-
ogy guidelines [15]. An evaluation by an autoimmune 
disease specialist was also performed in all patients with 
SLE, which included a complete physical examination 
and laboratory tests required to access systemic disease 
activity, which was scored using the Systemic Lupus Ery-
thematosus Disease Activity Index (SLEDAI) [16]. One 
eye per patient was randomly selected for the study.
Spectral‑domain optical coherence tomography imaging 
and layer segmentation
Peripapillary and macular tomographic scans were 
obtained with SD-OCT  (Spectralis® Heidelberg, software 
version 6.0 Heidelberg, Germany) in all participants after 
pupillary dilation. Only good quality scans, with a signal 
strength better than 20 (40 = maximum), with completely 
focused images, without artifacts or blank areas were 
considered in the analysis.
The pRNFL measurements employed a 12° circular 
scan centered on the optic nerve head, which corre-
sponds to a retinal diameter of approximately 3.46  mm 
in an eye with typical axial length and corneal curva-
ture. pRNFL thickness was determined globally (G) and 
for the six peripapillary sectors (TS—temporal superior, 
T—temporal, TI—temporal inferior, NI—nasal inferior, 
N—nasal, and NS—nasal superior) by the instrument’s 
built-in software, which automatically segments the 
internal limiting membrane (ILM) and the posterior bor-
der of the retinal nerve fiber layer (RNFL) (Fig. 1).
For macular measurements, a fast macular thickness 
OCT protocol was used, which consists of horizontal 
raster scans obtained in a 20 × 20° (5.8  mm × 5.8  mm) 
square centered on the fovea (25 high-resolution scans 
with nine frames per B-scan). Images were analyzed 
using Spectralis automatic segmentation software to cal-
culate individual retinal layer thickness values, namely, 
overall retinal thickness (RT), RNFL, ganglion cell layer 
(GCL), inner plexiform layer (IPL), inner nuclear layer 
(INL), outer plexiform layer (OPL), outer nuclear layer 
(ONL), photoreceptor layer (PRL) and retinal pigment 
epithelium (RPE). An Early Treatment Diabetic Retin-
opathy Study (ETDRS) plot was automatically projected 
onto the retina by Spectralis OCT software [17]. This plot 
Fig. 1 Thickness of the peripapillary retinal nerve fiber layer obtained by “RNFL Single Exam Report OU with FoDi™” (Spectralis Heidelberg; μm)
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consists of three concentric rings centered on the fovea, 
with 1-, 3- and 6-mm diameters. Two intersecting lines 
divide the two outer ETDRS rings into quadrants, gener-
ating nine sectors: C, S3, T3, I3, N3, S6, T6, I6 and N6 
(Fig. 2). Mean thickness values for all retinal layers were 
recorded for the nine ETDRS sectors.
Enhanced depth imaging scans were also obtained 
using the fast macular thickness OCT protocol to meas-
ure choroidal thickness (CT), according to a previously 
described method [18]. CT was measured manually, sub-
foveally and at 1000 µm superior, temporal, inferior and 
nasal to the fovea.
All OCT examinations were performed between 
2:00 PM and 4:00 PM by an ophthalmologist (J.T.F.) and 
were assessed by another ophthalmologist (A.D.S.), both 
masked to the patients’ diagnosis. Image quality, centra-
tion and segmentation were checked and corrected if 
necessary.
Statistical analysis
The characteristics of study participants were described 
using the mean (standard deviation: SD) or the median 
(interquartile range:  P25–P75) for continuous variables 
and frequencies (percentages) for categorical variables.
Univariable and multivariable linear regression mod-
els were used to identify the variables that may explain 
the variability of macular retinal layers and pRNFL thick-
nesses. The effect of potential confounders such as age, 
sex, spherical equivalent, BCVA, axial length, choroi-
dal thickness, intraocular pressure (IOP), mean arterial 
pressure (MAP), body mass index (BMI) and systemic 
medication was taken into account in this analysis. The 
selection of variables for the multivariable analysis was 
performed using the backward elimination method.
An analysis only for the SLE group was also performed 
to study the effect on retinal thickness of disease dura-
tion, hydroxychloroquine intake and cumulative dosage 
and systemic comorbidities such as neuropsychiatric 
SLE, lupus nephritis and antiphospholipid syndrome, 
among others, using the same regression models.
The normality assumption of the residuals was verified 
with the Shapiro–Wilk goodness-of-fit test. A level of sig-
nificance of α = 0.05 was considered. Data were analyzed 
using the Statistical Package for the Social Sciences for 
Windows, version 22.0 (IBM Corp. Released 2013. IBM 
SPSS Statistics for Windows, Version 22.0; IBM Corp, 
Armonk, NY).
Results
Patient demographics and clinical characteristics
A total of 68 eyes of 68 patients with SLE (58 women and 
10 men) and 50 eyes of 50 healthy controls (43 women 
and 7 men) were enrolled in this study. The clinical and 
demographic characteristics of the patients and controls 
are summarized in Table 1. The pharmacological history 
is summarized in Additional file 1.
Analysis of the peripapillary retinal nerve fiber layer
Univariable analysis revealed a statistically significant 
difference in pRNFL thickness in the TS and T sectors, 
which was lower in the SLE group (Additional file 2).
In multivariable linear regression models (Table  2), 
after adjusting for sex, age, BCVA, IOP, spherical equiv-
alent, axial length, BMI, MAP, and systemic medica-
tion, there was a statistically significant difference in 
pRNFL thickness for the global (p = 0.026), temporal 
superior (p = 0.007) and temporal sectors (p = 0.037), 
which was lower in the SLE group. Age was negatively 
associated with pRNFL in some sectors (G p < 0.001; TI 
p = 0.013; NS p = 0.013; N p = 0.025). Axial length was 
also negatively associated with pRNFL thickness in the G 
(p = 0.013) and NI (p = 0.007) sectors.
The results of the multivariable regression analy-
sis considering the SLE group alone are summarized in 
Table 3. Notably, chronic medication with antihyperten-
sive drugs, namely, calcium channel blockers or angi-
otensin-converting enzyme inhibitors, was associated 
with a thinner pRNFL in some sectors (G p = 0.009; TI 
p = 0.017; N p = 0.023; NS p = 0.006). Chronic medica-
tion with anticoagulants was negatively associated with 
pRNFL thickness in the G (p = 0.022), TI (p = 0.007), NI 
(p = 0.020) and NS (p = 0.037) sectors. Chronic medi-
cation with statins was also negatively associated with 
Fig. 2 Representative Spectralis Heidelberg SD‑OCT scans of the 
macular thickness map using the ETDRS protocol
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pRNFL thickness in two sectors: TI (p = 0.021) and NI 
(p = 0.020). Age and axial length also remained in the 
model in some pRNFL sectors.
Analysis of macular retinal layers thickness
The mean retinal layers thickness in the healthy control 
and SLE groups, as well as in the subgroup of patients 
with NP-SLE, is depicted in Fig. 3.
In the multivariable analysis, after considering age, sex, 
BCVA, IOP, spherical equivalent, axial length, BMI, MAP 
and systemic medication, there were no statistically sig-
nificant differences in overall RT or in most locations for 
the remaining retinal layers. The only exception was the 
photoreceptor (PR) layer.
The results in the PR layer were more consistent and 
were thinner in the SLE group. Multivariable regression 
analysis was also performed by dividing the SLE group 
according to disease duration: group I (< 5 years, n = 16), 
group II (5–10  years, n = 17) and group III (> 10  years, 
n = 35). After classifying the SLE group according to this 
parameter, we observed a reduction in PR layer thickness 
when compared with the healthy control group that was 
attenuated with increasing disease duration (Table  4). 
This pattern of PR thinning occurs in all macular sectors.
A multivariable regression analysis for the PR layer 
was also performed, considering the SLE group alone 
(Table 5). A higher SLEDAI score was associated with a 
reduction in PR layer thickness in the C (p = 0.015) and 
N3 (p = 0.050) sectors. NP-SLE diagnosis was associated 
with thinning of the PR layer in the C sector (p = 0.025). 
Chronic medication for hypertension (calcium chan-
nel blockers and angiotensin-converting enzyme inhibi-
tors) was associated with a thinner PR layer in the T3 
(p = 0.039) and N6 (p = 0.043) sectors. Chronic medi-
cation with statins was also negatively associated with 
PR layer thickness in two sectors: I3 (p = 0.028) and N3 
(p = 0.006). Finally, secondary Sjogren’s syndrome was 
associated with a thicker PR layer in the C (p = 0.015) and 
N3 (p = 0.048) sectors.
Discussion
In this study, we found evidence of retinal neurodegener-
ation in patients with SLE. Using SD-OCT, we compared 
pRNFL and macular layers thickness between patients 
Table 1 Demographic and clinical characteristics of the patients by group
The results are expressed as the mean (SD) or median  (P25–P75) for continuous variables or as n (%) for categorical variables
BCVA best corrected visual acuity, HCQ hydroxychloroquine, IOP intraocular pressure, logMAR logarithm of the minimum angle of resolution, MAP mean arterial 
pressure, NA not applicable, NP-SLE neuropsychiatric systemic lupus erythematosus, SLE systemic lupus erythematosus, SLEDAI Systemic Lupus Erythematosus Disease 
Activity Index
*Chi‑square test; remaining p‑values were obtained by the Mann–Whitney test
Variables SLE group (n = 68) Control group (n = 50) p‑value
Age, years 45.50 (12.67) 52.76 (14.45) 0.003
Female sex, n (%) 58 (85.3) 43 (86) 0.914*
Body mass index, kg/m2 24.64 (3.91) 25.79 (3.73) 0.070
BCVA, logMAR 0.010 (0.051) 0.005 (0.020) 0.890
IOP‑Goldmann, mm Hg 13.60 (2.88) 13.76 (2.55) 0.738
Spherical equivalent, D − 0.25 (− 1.0 to 0.25) 0.13 (− 0.63 to 1.0) 0.048
Axial length, mm 23.56 (1.00) 22.89 (0.96) < 0.001
MAP, mm Hg 88.71 (11.06) 91.92 (13.11) 0.114
SLE duration, years 11.0 (6.25–19.0) NA
SLEDAI 2 (0–4) NA
HCQ
 Daily dose, mg 329 (96) NA
 Cumulative dose, g 778 (228.1–1606.0) NA
 Therapy duration, years 5.30 (1.81–11.83) NA
 Daily dose/weight, mg/kg 5.02 (1.61) NA
 Cumulative dose/weight, g/kg 10.76 (3.16–25.47) NA
NP‑SLE, n (%) 19 (27.9) NA
 Central NP‑SLE, n (%) 16 (23.5) NA
 Peripheral NP‑SLE, n (%) 3 (4.4) NA
Lupus nephritis, n (%) 18 (26.5) NA
Antiphospholipid syndrome, n (%) 21 (30.9) NA
Sjogren’s syndrome, n (%) 5 (7.4) NA
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with SLE without ophthalmologic manifestations and 
healthy controls. A significant decrease in the pRNFL as 
well as in the macular photoreceptor layer was observed 
in patients with SLE.
It is believed that patients with SLE have chronic low-
grade CNS inflammation beginning early in the course 
of the disease [19]. This inflammatory process pro-
foundly impacts the continuous crosstalk held between 
the CNS and the immune system, resulting in the emer-
gence of symptoms such as depression, anxiety disorders 
or psychosis [20]. Its pathophysiology is complex and 
multifactorial, involving immune complex depositions, 
autoantibody-mediated neuronal cell damage, inflamma-
tory and thrombotic microangiopathy, intrathecal syn-
thesis of proinflammatory cytokines and disruption of 
the blood–brain barrier [4]. This inflammatory microen-
vironment ultimately leads to mitochondrial damage and 
disturbance of neuron-glia metabolic coupling, resulting 
in a marked reduction in synaptic activity and neuronal 
death, which are the hallmarks of neurodegeneration [1, 
4]. Indeed, the cerebrospinal fluid of patients with SLE 
presents increased levels of neurofilament (a neuronal 
degradation product), Tau (an axonal degeneration prod-
uct) and astroglial fibrillary acidic protein (a marker of 
neuronal damage and gliosis) compared to that of healthy 
controls [21, 22].
Peripapillary RNFL thinning, specifically involving the 
temporal sectors, is a proven biomarker of neurodegen-
eration in several diseases, such as Alzheimer’s disease 
[9], Parkinson’s disease [10] or multiple sclerosis [8]. In 
this study, we documented a significant reduction in the 
pRNFL in the global, temporal superior and temporal 
Table 2 Results of  multivariable regression models—
dependent variable: pRNFL thickness
*Reference category: control group. Age: for each 10‑year increase. p‑values 
were obtained by linear regression models
G global, N nasal, NI nasal inferior, NS nasal superior, pRNFL peripapillary retinal 
nerve fiber layer, SLE systemic lupus erythematosus, T temporal, TI temporal 
inferior, TS temporal superior
Model Coefficient 
estimate
95% confidence interval p‑value
Dependent variable: pRNFL thickness G
 SLE group* − 3.87 − 7.27 to − 0.48 0.026
 Male sex − 4.93 − 9.39 to − 0.46 0.031
 Age (years) − 2.60 − 3.87 to − 1.32 < 0.001
 Axial length (mm) − 2.23 − 3.97 to − 0.49 0.013
 Benzodiazepines 7.37 1.70 to 13.04 0.011
Dependent variable: pRNFL thickness TS
 SLE group* − 7.94 − 13.64 to − 2.38 0.007
Dependent variable: pRNFL thickness T
 SLE group* − 4.14 − 8.03 to − 0.25 0.037
Dependent variable: pRNFL thickness TI
 SLE group* − 3.95 − 11.17 to 3.28 0.282
 Age (years) − 3.28 − 5.86 to − 0.69 0.013
Dependent variable: pRNFL thickness NI
 SLE group* 6.39 − 2.59 to 15.36 0.161
 Axial length (mm) − 5.91 − 10.21 to − 1.61 0.007
Dependent variable: pRNFL thickness N
 SLE group* − 2.42 − 6.94 to 2.10 0.291
 Age (years) − 1.86 − 3.47 to − 0.24 0.025
Dependent variable: pRNFL thickness NS
 SLE group* − 7.04 − 14.53 to 0.46 0.065
 Age (years) − 3.40 − 6.08 to − 0.72 0.013
Table 3 Results of  multivariable regression models 
for the SLE group—dependent variable: pRNFL thickness
Age: for each 10‑year increase. Corticosteroid is expressed as the daily dose of 
prednisone equivalent. p‑values were obtained by linear regression models
ACE angiotensin‑converting enzyme, G global, IOP intraocular pressure, N nasal, 
NI nasal inferior, NS nasal superior, pRNFL peripapillary retinal nerve fiber layer, 







Dependent variable: pRNFL thickness G
 Age (years) − 3.02 − 4.91 to − 1.13 0.002
 Axial length (mm) − 3.98 − 6.34 to − 1.62 0.001
 Calcium channel 
blocker
− 10.66 − 18.56 to − 2.77 0.009
 Anticoagulant − 6.71 − 12.42 to − 1.00 0.022
Dependent variable: pRNFL thickness TS
 Age (years) − 3.38 − 6.55 to − 0.22 0.037
 Axial length (mm) − 4.12 − 8.13 to − 0.12 0.044
Dependent variable: pRNFL thickness T
 Sjogren syndrome − 10.36 − 19.38 to − 1.35 0.025
Dependent variable: pRNFL thickness TI
 IOP (mm Hg) − 2.15 − 3.60 to − 0.71 0.004
 Calcium channel 
blocker
− 17.97 − 32.64 to − 3.30 0.017
 Anticoagulant − 15.08 − 25.84 to − 4.31 0.007
 Statin − 13.94 − 25.73 to − 2.15 0.021
Dependent variable: pRNFL thickness NI
 Axial length (mm) − 9.03 − 14.59 to − 3.47 0.002
 Anticoagulant − 17.16 − 31.56 to − 2.76 0.020
 Statin − 18.56 − 34.09 to − 3.03 0.020
Dependent variable: pRNFL thickness N
 Body mass index (kg/
m2)
− 0.80 − 1.58 to − 0.01 0.046
 ACE inhibitor − 10.03 − 18.61 to − 1.45 0.023
Dependent variable: pRNFL thickness NS
 Axial length (mm) − 5.47 − 9.46 to − 1.47 0.008
 Calcium channel 
blocker
− 20.07 − 34.01 to − 6.12 0.006
 Anticoagulant − 11.34 − 21.99 to − 0.69 0.037
 Corticosteroid (mg) 0.12 0.05 to 0.18 0.001
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sectors in patients with SLE compared to healthy con-
trols. This thinning was independent of sex, age, BCVA, 
IOP, spherical equivalent, axial length, BMI, MAP and 
systemic medication. Age and axial length were also 
negatively associated with pRNFL thickness in some sec-
tors. A multivariable analysis in the SLE group revealed 
that patients under chronic medication with anticoagu-
lants, statins, angiotensin-converting enzyme inhibitors 
(ACEIs) and calcium channel blockers (CCBs) had thin-
ner pRNFLs. Previous studies of pRNFL in SLE are scarce 
and had inconsistent results. Shulman et al. found a trend 
towards lower pRNFL thickness in SLE, without statisti-
cal significance. However, their sample was small, includ-
ing only 21 patients with SLE and 11 healthy controls 
[12]. On the other hand, Liu et  al. [11], in a study with 
31 patients with SLE and 16 healthy controls, reported 
significant thinning in the global, temporal superior 
and nasal pRNFL. Additionally, they described a posi-
tive correlation between pRNFL thickness in the tempo-
ral superior and temporal inferior sectors and cognitive 
test scores. However, none of the abovementioned stud-
ies included a multivariable analysis; thus, the results for 
pRNFL thickness were not corrected for the effects of 
confounding factors such as age or axial length.
Macular layers analysis revealed a significant reduc-
tion in PR layer thickness in patients with SLE com-
pared to healthy controls. Photoreceptors are the 
most energy-demanding neurons in the CNS [23]. 
Their metabolic demands are fulfilled by the choroi-
dal circulation, particularly the choriocapillaris. Lupus 
choroidopathy has been extensively described and is 
characterized by choroidal vasculitis, as well as com-
plement and immunoglobulin deposition in choroi-
dal vessels, resulting in long-term choroidal ischemia 
[24]. Changes in choroidal circulation have also been 
described even in asymptomatic patients [25–27]. Vas-
culopathy of the choriocapillary layer may thus result 
in chronic ischemia of the outer retinal layers, particu-
larly the PR, increasing reactive oxygen species produc-
tion. This adverse environment reduces mitochondrial 
Fig. 3 Graphs displaying individual retinal layer thickness in the nine ETDRS areas for the SLE group, the control group and the neuropsychiatric SLE 
subgroup. a RT; b RNFL; c GCL; d IPL; e INL; f OPL; g ONL; h PRL; i RPE
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biogenesis, generating an energy crisis that causes the 
PR degeneration observed in patients with SLE [1]. 
Specific autoantibodies targeting photoreceptors are 
another proposed mechanism [28]. Destruction of 
the PR cell layer has been documented histologically 
in mouse models of SLE, along with thickening of the 
wall of the choroidal arterioles and occlusion of the 
choriocapillaries [29]. Ocular histopathologic reports 
on patients with lupus are rare in the literature. Cao 
et  al. reported a case with diffuse loss of PR without 
significant signs of tissue inflammation. Additionally, 
the optic nerves presented loss of axons and thickened 
septae, with slight macrophage infiltration and micro-
glial accumulation [28]. Thinning of the PR cell layer as 
an early sign of retinal neurodegeneration has already 
been described in other entities, such as diabetes mel-
litus and metabolic syndrome, in which microvascular 
disease assumes a central role in the pathogenesis [30, 
31].
Considering patients with SLE only, the multivariable 
analysis of PR layer thickness revealed that patients with 
NP-SLE diagnosis had thinner values for the central sec-
tor. A higher disease activity index was also negatively 
associated with PR layer thickness in the central and N3 
subfields. Patients with secondary Sjogren’s syndrome 
presented a thicker PR layer in the central and N3 sec-
tors; however, this result must be interpreted with cau-
tion since there were only five patients with Sjogren’s 
syndrome. A thinner PR layer in some sectors of patients 
under chronic medication with antihypertensives (ACEIs 
and CCBs) and statins is also worth noting. This analysis 
suggests that patients with clinical neurological involve-
ment as well as those with poor systemic disease control 
are more prone to PR degeneration. Similar to the pRNFL 
analysis, patients on chronic medication for hyperten-
sion or hypercholesterolemia are more susceptible to 
PR degeneration, suggesting a deleterious role of cardio-
vascular risk factors. A negative association between PR 
layer thickness and HCQ treatment time was observed in 
the S6 sector. However, the absence of significant associa-
tions in other ETDRS locations or with cumulative HCQ 
dosage, as well as the absence of characteristic visual field 
defects and fundus autofluorescence abnormalities, are 
arguments against the existence of HCQ macular toxicity.
Another interesting finding in this investigation was 
the pattern of PR layer thinning throughout the course 
of the disease. PR layer thinning is more marked in 
those patients with shorter disease duration (up to 
5  years), followed by those with intermediate dura-
tion and then those with longer disease duration (more 
than 10 years). This pattern, which was observed in all 
ETDRS areas, may be interpreted as a result of retinal 
remodeling. Remodeling is a process in which the loss 
of cones and/or rods results in neural retina deaffer-
entation, which in turn results in a series of changes 
to retinal organization [32]. Retinal remodeling has 
been described following retinal detachment [33], age-
related macular degeneration [34] or any other situ-
ation where photoreceptors are lost, especially cones 
[32]. Regardless of the initiating event, the subsequent 
retinal changes lead to revisions in neuronal morphol-
ogy and organization through neuritogenesis and cell 
migration, reorganization of synaptic connectivity and 
intracellular molecular processes [32]. This process of 
retinal plasticity may thus explain the partial recov-
ery in PR layer thickness observed with longer disease 
duration.
Table 4 Results of multivariable regression models for PR 
layer thickness
*Reference category: healthy control group. p‑values were obtained by linear 
regression models
PR photoreceptor, Group I up to 5 years of disease duration, Group II 5–10 years, 
Group III more than 10 years
Model* Coefficient 
estimate
95% confidence interval p‑value
Dependent variable: PR layer thickness at S3 sector
 Group I − 1.60 − 3.31 to 0.11 0.066
 Group II − 1.51 − 3.18 to 0.16 0.076
 Group III − 0.53 − 1.84 to 0.78 0.426
Dependent variable: PR layer thickness at T3 sector
 Group I − 1.57 − 3.36 to 0.22 0.084
 Group II − 1.08 − 2.83 to 0.66 0.222
 Group III − 0.86 − 2.23 to 0.51 0.217
Dependent variable: PR layer thickness at I3 sector
 Group I − 1.44 − 2.77 to − 0.11 0.035
 Group II − 0.79 − 2.10 to 0.51 0.231
 Group III − 0.70 − 1.72 to 0.33 0.180
Dependent variable: PR layer thickness at S6 sector
 Group I − 1.74 − 3.05 to − 0.43 0.010
 Group II − 1.51 − 2.79 to − 0.22 0.022
 Group III − 1.20 − 2.21 to − 0.19 0.020
Dependent variable: PR layer thickness at T6 sector
 Group I − 1.90 − 3.11 to − 0.68 0.003
 Group II − 1.52 − 2.71 to − 0.33 0.013
 Group III − 0.95 − 1.88 to − 0.02 0.046
Dependent variable: PR layer thickness at I6 sector
 Group I − 1.24 − 2.32 to − 0.15 0.026
 Group II − 1.18 − 2.24 to − 0.12 0.029
 Group III − 1.04 − 1.88 to − 0.21 0.014
Dependent variable: PR layer thickness at N6 sector
 Group I − 1.71 − 2.93 to − 0.49 0.007
 Group II − 1.40 − 2.60 to − 0.21 0.022
 Group III − 1.18 − 2.11 to − 0.24 0.014
Page 9 of 11Dias‑Santos et al. Int J Retin Vitr            (2020) 6:15  
Some studies evaluated subclinical retinal changes in 
other autoimmune systemic disorders using SD-OCT. A 
study in patients with rheumatoid arthritis revealed no 
significant changes in pRNFL or total foveal thickness 
compared to healthy controls [35]. On the other hand, 
patients with primary Sjogren’s syndrome present a sig-
nificant reduction in pRNFL as well as in macular GCL 
compared to healthy controls [36]. Patients with Behçet’s 
disease also present significant thinning in the pRNFL 
[37]. Patients with neuro-Behçet present not only a 
reduction in pRNFL but also a reduction in total macu-
lar thickness compared to healthy controls [38]. Patients 
with Susac syndrome present a reduction in pRNFL, par-
ticularly in the nasal quadrant. These patients also pre-
sent an abnormal foveal contour with a reduction in the 
thickness of the inner macular layers [39–41].
This study has some limitations. The first is the size 
of the sample. Despite being the study with the larg-
est sample in this field, the sample size may have lim-
ited the ability to find differences in some subsets of 
patients, such as those with NP-SLE. However, sig-
nificant thinning in the PR layer was observed in this 
subgroup in the central ETDRS subfield. Second, our 
assessment of disease duration is based on the time of 
the diagnosis, which, in some cases, may underesti-
mate the real time of disease. Finally, retinal segmen-
tation was performed by automatic software, which is 
susceptible to some mistakes. Regarding the pRNFL, 
decreased scan quality, tilted disc, older age and thin-
ner pRNFL tend to underestimate automatic pRNFL 
thickness measurement. However, this inaccuracy can 
be significantly reduced by postsegmentation inspec-
tion and refinement by a trained operator [42, 43]. 
Regarding individual macular layer thickness measure-
ments, Spectralis segmentation software has proven 
high repeatability and reproducibility for all layers in 
all nine ETDRS areas [7, 44]. Nevertheless, its accu-
racy may be significantly affected by image quality or 
marked anatomical distortion [7, 45]. In our study, 
we only included participants without retinal or optic 
nerve pathology in whom good quality scans could be 
obtained. Additionally, detailed inspection and man-
ual refinement by an ophthalmologist masked to the 
patients’ diagnosis was performed whenever segmenta-
tion was deemed inaccurate.
Table 5 Results of multivariable regression models for PR layer thickness in the SLE group
No multiple model was achieved for the T6 and I6 sectors. p‑values were obtained by linear regression models
ACE angiotensin‑converting enzyme, HCQ hydroxychloroquine, NP-SLE neuropsychiatric systemic lupus erythematosus, PR photoreceptor, SLEDAI Systemic Lupus 
Erythematosus Disease Activity Index
Model* Coefficient estimate 95% confidence interval p‑value
Dependent variable: PR layer thickness at C sector
 NP‑SLE − 2.83 − 5.29 to − 0.37 0.025
 Sjogren’s syndrome 5.05 0.71 to 9.40 0.023
 SLEDAI − 0.29 − 0.51 to − 0.06 0.015
 Body mass index (kg/m2) − 0.31 − 0.60 to − 0.02 0.038
Dependent variable: PR layer thickness at S3 sector
 Benzodiazepine 2.67 0.35 to 4.99 0.025
Dependent variable: PR layer thickness at T3 sector
 Calcium channel blocker − 2.68 − 5.23 to − 0.14 0.039
Dependent variable: PR layer thickness at I3 sector
 Statin − 1.84 − 3.48 to − 0.20 0.028
Dependent variable: PR layer thickness at N3 sector
 Sjogren’s syndrome 2.38 0.2 to 4.74 0.048
 SLEDAI − 0.13 − 0.26 to 0.00 0.050
 Statin − 2.44 − 4.15 to − 0.73 0.006
Dependent variable: PR layer thickness at S6 sector
 Benzodiazepine 1.95 0.23 to 3.68 0.027
 HCQ treatment time (years) − 0.83 − 0.16 to 0.00 0.041
Dependent variable: PR layer thickness at N6 sector
 Axial length (mm) 0.53 0.01 to 1.05 0.045
 ACE inhibitor − 1.50 − 2.95 to − 0.05 0.043
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Conclusions
In conclusion, this study, which was the first to per-
form a complete SD-OCT segmentation analysis of all 
retinal layers in patients with SLE, revealed thinning of 
the pRNFL and PR layer in these patients compared to 
healthy controls. Based on the existing literature, these 
changes might constitute an early sign of retinal neurode-
generation, probably occurring as a result of an apoptotic 
process in the context of a chronic low-grade inflamma-
tory microenvironment. Further research in this area 
should try to explore a possible relationship between the 
findings of this study and changes in structural and func-
tional CNS imaging.
Supplementary information
Supplementary information accompanies this paper at https ://doi.
org/10.1186/s4094 2‑020‑00219 ‑y.
Additional file 1: Table S1. Pharmacological history of the patients by 
group. 
Additional file 2: Table S2. Peripapillary retinal nerve fiber layer thickness 




ADS: conception and design, acquisition, analysis and interpretation of 
data, draft of the article; JTF, MFMF: conception and design, acquisition and 
interpretation of data; SP: acquisition and analysis of the data; JPC: conception 
and design, interpretation of data; MA, ALP, RP: conception and design and 
interpretation of data. All authors read and approved the final manuscript.
Funding
A grant for this study was given by José de Mello Saúde—Hospital CUF 
Descobertas.
Availability of data and materials
The datasets used and/or analyzed during the current study are available from 
the corresponding author on reasonable request.
Ethics approval and consent to participate
The study was performed in accordance with the Declaration of Helsinki and 





The authors declare that they have no competing interests.
Author details
1 Department of Ophthalmology, Centro Hospitalar Universitário de Lisboa 
Central, Lisbon, Portugal. 2 Department of Ophthalmology, Hospital CUF 
Descobertas, Lisbon, Portugal. 3 NOVA Medical School, Universidade NOVA de 
Lisboa, Lisbon, Portugal. 4 Autoimmune Disease Unit, Unidade de Doenças 
Auto‑imunes/Serviço Medicina 3, Hospital de Santo António dos Capuchos, 
Centro Hospitalar Universitário de Lisboa Central, Lisbon, Portugal. 5 Epide‑
miology and Statistics Unit, Research Center, Centro Hospitalar Universitário 
de Lisboa Central, Lisbon, Portugal. 6 CEAUL (Center of Statistics and its 
Applications), Lisbon University, Lisbon, Portugal. 7 Autoimmune Disease Unit, 
Unidade de Doenças Auto‑imunes/Serviço de Medicina 7.2, Hospital Curry 
Cabral, Centro Hospitalar Universitário de Lisboa Central, Lisbon, Portugal. 
8 Instituto Gulbenkian de Ciência, Oeiras, Portugal. 9 Department of Oph‑
thalmology, Centro Hospitalar Universitário de Coimbra, Coimbra, Portugal. 
10 Faculty of Medicine, University of Coimbra, Coimbra, Portugal. 11 Serviço de 
Oftalmologia, Hospital de Santo António dos Capuchos, Alameda de Santo 
António dos Capuchos, 1169‑050 Lisbon, Portugal. 
Received: 2 November 2019   Accepted: 15 April 2020
References
 1. Sankowski R, Mader S, Valdés‑Ferrer SI. Systemic inflammation and the 
brain: novel roles of genetic, molecular, and environmental cues as 
drivers of neurodegeneration. Front Cell Neurosci. 2015;9:28. https ://doi.
org/10.3389/fncel .2015.00028 .
 2. Liang MH, Corzillius M, Bae SC, Lew RA, Fortin PR, Gordon C, et al. The 
American College of Rheumatology nomenclature and case definitions 
for neuropsychiatric lupus syndromes. Arthritis Rheum. 1999;42:599–608.
 3. Unterman A, Nolte JES, Boaz M, Abady M, Shoenfeld Y, Zandman‑Godd‑
ard G. Neuropsychiatric syndromes in systemic lupus erythematosus: a 
meta‑analysis. Semin Arthritis Rheum. 2011;41:1–11.
 4. Dias‑Santos A, Proença RP, Tavares Ferreira J, Pinheiro S, Cunha JP, 
Proença R, et al. The role of ophthalmic imaging in central nervous 
system degeneration in systemic lupus erythematosus. Autoimmun Rev. 
2018;17:617–24.
 5. Zhu CM, Ma Y, Xie L, Huang JZ, Sun ZB, Duan SX, et al. Spatial working 
memory impairment in patients with non‑neuropsychiatric systemic 
lupus erythematosus: a blood‑oxygen‑level dependent functional mag‑
netic resonance imaging study. J Rheumatol. 2017;44:201–8.
 6. Jeltsch‑David H, Muller S. Autoimmunity, neuroinflammation, patho‑
gen load: a decisive crosstalk in neuropsychiatric SLE. J Autoimmun. 
2016;74:13–26.
 7. Ctori I, Huntjens B. Repeatability of foveal measurements using spectralis 
optical coherence tomography segmentation software. PLoS ONE. 
2015;10:e0129005.
 8. Toledo J, Sepulcre J, Salinas‑Alaman A, García‑Layana A, Murie‑Fernandez 
M, Bejarano B, et al. Retinal nerve fiber layer atrophy is associated 
with physical and cognitive disability in multiple sclerosis. Mult Scler. 
2008;14:906–12.
 9. Cunha JP, Proença R, Dias‑Santos A, Almeida R, Águas H, Alves M, et al. 
OCT in Alzheimer’s disease: thinning of the RNFL and superior hemiret‑
ina. Graefe’s Arch Clin Exp Ophthalmol. 2017;255:1827–35.
 10. Inzelberg R, Ramirez JA, Nisipeanu P, Ophir A. Retinal nerve fiber layer 
thinning in Parkinson disease. Vis Res. 2004;44:2793–7.
 11. Liu GY, Utset TO, Bernard JT. Retinal nerve fiber layer and macular thin‑
ning in systemic lupus erythematosus: an optical coherence tomography 
study comparing SLE and neuropsychiatric SLE. Lupus. 2015;24:1169–76.
 12. Shulman S, Shorer R, Wollman J, Dotan G, Paran D. Retinal nerve fiber 
layer thickness and neuropsychiatric manifestations in systemic lupus 
erythematosus. Lupus. 2017;26:1420–5.
 13. Conigliaro P, Triggianese P, Draghessi G, Canofari C, Aloe G, Chimenti 
MS, et al. Evidence for the detection of subclinical retinal involvement 
in systemic lupus erythematosus and Sjögren syndrome: a potential 
association with therapies. Int Arch Allergy Immunol. 2018;177:45–56.
 14. Hochberg MC. Updating the American College of Rheumatology revised 
criteria for the classification of systemic lupus erythematosus. Arthritis 
Rheum. 1997;40:1725.
 15. Marmor MF, Kellner U, Lai TYY, Melles RB, Mieler WF, Lum F. Recommenda‑
tions on screening for chloroquine and hydroxychloroquine retinopathy 
(2016 Revision). Ophthalmology. 2016;123:1386–94.
 16. Bombardier C, Gladman DD, Urowitz MB, Caron D, Chang CH, Austin A, 
et al. Derivation of the sledai. A disease activity index for lupus patients. 
Arthritis Rheum. 1992;35:630–40.
 17. Early Treatment Diabetic Retinopathy Study Research Group. Photocoag‑
ulation for diabetic macular edema: early treatment diabetic retinopathy 
study report number 1. Arch Ophthalmol. 1985;103:1796–806.
 18. Spaide RF, Koizumi H, Pozonni MC. Enhanced depth imaging 
spectral‑domain optical coherence tomography. Am J Ophthalmol. 
2008;146:496–500.
Page 11 of 11Dias‑Santos et al. Int J Retin Vitr            (2020) 6:15  
•
 
fast, convenient online submission
 •
  
thorough peer review by experienced researchers in your field
• 
 
rapid publication on acceptance
• 
 
support for research data, including large and complex data types
•
  
gold Open Access which fosters wider collaboration and increased citations 
 
maximum visibility for your research: over 100M website views per year •
  At BMC, research is always in progress.
Learn more biomedcentral.com/submissions
Ready to submit your research ?  Choose BMC and benefit from: 
 19. Ramage AE, Fox PT, Brey RL, Narayana S, Cykowski MD, Naqibud‑
din M, et al. Neuroimaging evidence of white matter inflammation 
in newly diagnosed systemic lupus erythematosus. Arthritis Rheum. 
2011;63:3048–57.
 20. Kayser MS, Dalmau J. The emerging link between autoimmune disor‑
ders and neuropsychiatric disease. J Neuropsychiatry Clin Neurosci. 
2011;23:90–7.
 21. Trysberg E, Höglund K, Svenungsson E, Blennow K, Tarkowski A. 
Decreased levels of soluble amyloid beta‑protein precursor and beta‑
amyloid protein in cerebrospinal fluid of patients with systemic lupus 
erythematosus. Arthritis Res Ther. 2004;6:R129–36.
 22. Trysberg E, Nylen K, Rosengren LE, Tarkowski A. Neuronal and astrocytic 
damage in systemic lupus erythematosus patients with central nervous 
system involvement. Arthritis Rheum. 2003;48:2881–7.
 23. Ames A. Energy requirements of CNS cells as related to their function 
and to their vulnerability to ischemia: a commentary based on studies on 
retina. Can J Physiol Pharmacol. 1992;70:S158–64.
 24. Nag T, Wadhwa S. Vascular changes of the retina and choroid in systemic 
lupus erythematosus: pathology and pathogenesis. Curr Neurovasc Res. 
2006;3:159–68.
 25. Gharbiya M, Pecci G, Baglio V, Gargiulo A, Allievi F, Balacco‑Gabrieli C. 
Indocyanine green angiographic findings for patients with systemic 
lupus erythematosus nephropathy. Retina. 2006;26:159–64.
 26. Altinkaynak H, Duru N, Uysal BS, Erten Ş, Kürkcüoğlu PZ, Yüksel N, et al. 
Choroidal thickness in patients with systemic lupus erythematosus ana‑
lyzed by spectral‑domain optical coherence tomography. Ocul Immunol 
Inflamm. 2015. https ://doi.org/10.3109/09273 948.2015.10067 90.
 27. Baglio V, Gharbiya M, Balacco‑Gabrieli C, Mascaro T, Gangemi C, di Franco 
M, et al. Choroidopathy in patients with systemic lupus erythematosus 
with or without nephropathy. J Nephrol. 2011;24:522–9.
 28. Cao X, Bishop RJ, Forooghian F, Cho Y, Fariss RN, Chan C‑C. Autoimmune 
retinopathy in systemic lupus erythematosus: histopathologic features. 
Open Ophthalmol J. 2009;3:20–5.
 29. Nakamura A, Yokoyama T, Kodera S, Zhang D, Hirose S. Ocular fundus 
lesions in systemic lupus erythematosus model mice. J Jpn Ophthalmol 
Soc. 1998;102:8–14.
 30. Tavares Ferreira J, Alves M, Dias‑Santos A, Costa L, Santos BO, Cunha JP, 
et al. Retinal neurodegeneration in diabetic patients without diabetic 
retinopathy. Investig Ophthalmol Vis Sci. 2016;57:6455–60.
 31. Karaca C, Karaca Z. Beyond hyperglycemia, evidence for retinal neu‑
rodegeneration in metabolic syndrome. Investig Ophthalmol Vis Sci. 
2018;59:1360–7.
 32. Jones BW, Pfeiffer RL, Ferrell WD, Watt CB, Marmor M, Marc RE. Retinal 
remodeling in human retinitis pigmentosa. Exp Eye Res. 2016;150:149–65.
 33. Lewis GP, Linberg KA, Fisher SK. Neurite outgrowth from bipolar and hori‑
zontal cells after experimental retinal detachment. Investig Ophthalmol 
Vis Sci. 1998;39:424–34.
 34. Sullivan R, Penfold P, Pow DV. Neuronal migration and glial remodeling in 
degenerating retinas of aged rats and in nonneovascular AMD. Investig 
Ophthalmol Vis Sci. 2003;44:856–65.
 35. Tetikoglu M, Temizturk F, Sagdik HM, Aktas S, Ozcura F, Ozkan Y, et al. 
Evaluation of the choroid, fovea, and retinal nerve fiber layer in patients 
with rheumatoid arthritis. Ocul Immunol Inflamm. 2017;25:210–4.
 36. Yang JM, Sung MS, Ji YS, Heo H, Park SW. Analysis of clinical factors 
associated with retinal morphological changes in patients with primary 
sjögren’s syndrome. PLoS ONE. 2016;11:e0157995.
 37. Oray M, Onal S, Bayraktar S, Izgi B, Tugal‑Tutkun I. Nonglaucomatous local‑
ized retinal nerve fiber layer defects in Behçet uveitis. Am J Ophthalmol. 
2015;159:475–481.e1.
 38. Ucar D, Uygunoglu U, Dikkaya F, Yıldırım Y, Yuksel‑Elgin C, Saip S, et al. 
Retinal nerve fiber layer structure abnormalities in patients with Neuro‑
Behcet’s disease. Graefe’s Arch Clin Exp Ophthalmol. 2015;253:1181–5.
 39. Brandt AU, Zimmermann H, Kaufhold F, Promesberger J, Schippling S, 
Finis D, et al. Patterns of retinal damage facilitate differential diagnosis 
between Susac syndrome and MS. PLoS ONE. 2012;7:e38741.
 40. Bernard JT, Romero R, Agrawal K, Jager R, Rezania K. Optical coherence 
tomography in Susac’s syndrome. Mult Scler Relat Disord. 2014;3:110–6.
 41. Ringelstein M, Albrecht P, Kleffner I, Bühn B, Harmel J, Müller AK, et al. 
Retinal pathology in Susac syndrome detected by spectral‑domain opti‑
cal coherence tomography. Neurology. 2015;85:610–8.
 42. Mansberger SL, Menda SA, Fortune BA, Gardiner SK, Demirel S. Auto‑
mated segmentation errors when using optical coherence tomography 
to measure retinal nerve fiber layer thickness in glaucoma. Am J Ophthal‑
mol. 2017;174:1–8.
 43. Ye C, Yu M, Leung CKS. Impact of segmentation errors and retinal blood 
vessels on retinal nerve fibre layer measurements using spectral‑domain 
optical coherence tomography. Acta Ophthalmol. 2016;94:e211–9.
 44. Çetinkaya E, Duman R, Duman R, Sabaner MC. Repeatability and repro‑
ducibility of automatic segmentation of retinal layers in healthy subjects 
using Spectralis optical coherence tomography. Arq Bras Oftalmol. 
2017;80:378–81.
 45. Balasubramanian M, Bowd C, Vizzeri G, Weinreb RN, Zangwill LM. Effect of 
image quality on tissue thickness measurements obtained with spectral 
domain‑optical coherence tomography. Opt Express. 2009;17:4019.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in pub‑
lished maps and institutional affiliations.
